Circassia Pharmaceuticals (CSSPF) AI Stock Analysis

Circassia Pharmaceuticals

(Other OTC:CSSPF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue growth and profitabilitySustained multi-year revenue expansion, combined with a healthy operating margin, indicates stronger demand and improving operating scale. The shift from earlier losses to consistent profitability supports reinvestment, resilience, and the potential for durable earnings generation over coming quarters.

Negative Factors

Gross-margin pressureThe gross-margin decline indicates that recent revenue growth has not translated fully into stable underlying economics. If mix, pricing, or cost pressure persists, it could constrain operating leverage and make future profit expansion more dependent on continued volume growth or expense control.

Circassia Pharmaceuticals (CSSPF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $273.94M
Dividend Yield: 2.32%
Average Volume (3M): 700
Price to Earnings (P/E): 39.9
Beta (1Y): 4.05
Revenue Growth: 7.10%
EPS Growth: 38.04%
Country: US
Employees: 97
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Circassia Pharmaceuticals Business Overview & Revenue Model

Company Description

NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic too...

Circassia Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CSSPF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:BVXP	89Outperform	GBP 104.50M	14.14	67.81%	7.32%	-1.10%	0.32%
GB:EKF	64Neutral	GBP 102.71M	40.52	3.58%	―	2.26%	-57.04%
GB:DXRX	59Neutral	GBP 172.63M	-632.81	-0.68%	―	20.14%	82.22%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:ABDX	46Neutral	GBP 22.75M	-16.36	-34.31%	―	30.42%	43.16%
GB:AGY	42Neutral	GBP 253.30M	-3.53	409.00%	―	2.94%	-32.00%

* Healthcare Sector Average

Performance Comparison

CSSPF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CSSPF	Circassia Pharmaceuticals	0.89	0.04	5.06%
GB:AGY	Allergy Therapeutics	3.50	-4.95	-58.58%
GB:BVXP	Bioventix plc	2050.00	32.34	1.60%
GB:EKF	EKF Diagnostics Holdings	23.50	-2.50	-9.62%
GB:DXRX	Diaceutics Plc	202.50	40.00	24.62%
GB:ABDX	Abingdon Health PLC	9.00	2.75	44.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Circassia Pharmaceuticals AI Stock Analysis